PharmaCan Capital Corp. Announces Approval of Increased Production Capacity at Whistler Medical Marijuana Company

TORONTO, ONTARIO--(Marketwired - Dec. 29, 2014) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES

PharmaCan Capital Corp. (TSX VENTURE:MJN) ("PharmaCan") is pleased to announce that on December 24, 2014, Whistler Medical Marijuana Company ("WMMC"), a Licensed Producer under the Marihuana for Medical Purposes Regulations ("MMPR"), received written approval from Health Canada, as required under the MMPR, to begin producing medical marijuana in an additional three new production rooms. These new rooms provide a substantial increase in WMMC's square footage, with the company now having a total of approximately 12,500 square feet.

"This is a tremendous milestone for WMMC and a testament to the company's regulatory compliance, operational excellence, and proven track record" said Paul Rosen, PharmaCan's President & CEO. "PharmaCan is very pleased that WMMC's increased production capacity will enable it to expand upon its commitment to providing patients with 100% certified organic, non-irradiated, and pesticide free medical marijuana."

WMMC, based in Whistler, British Columbia, received its MMPR license in February 2014. WMMC is certified organic by the Fraser Valley Organic Producers Association. PharmaCan has a 21.4% ownership interest in WMMC.

PharmaCan

PharmaCan is a company in the business of investing in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations ("MMPR"). PharmaCan has a diversified portfolio of investments including investments in three of the fifteen companies that are listed on Heath Canada's website as licensed to produce and sell medical marijuana as well as another two of the eight companies that are listed on Health Canada's website as licensed to produce medical marijuana.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

PharmaCan Capital Corp.
Paul Rosen
Investor Relations
(416) 504-0004
This email address is being protected from spambots. You need JavaScript enabled to view it.

Navigator Ltd.
Deirdre McMurdy
Media Relations
(416) 642-6339
This email address is being protected from spambots. You need JavaScript enabled to view it.